On this page
TRIDERM
Triamcinolone Acetonide · Cream
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 088042-001 | TRIDERM | CREAM | TRIAMCINOLONE ACETONIDE | Prescription | AT | ||
| 088042-002 | TRIDERM | CREAM | TRIAMCINOLONE ACETONIDE | Prescription | AT | ||
| 088042-003 | TRIDERM | CREAM | TRIAMCINOLONE ACETONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 5 | Labeling | Approved | January 7, 2015 | — |
| Supplement | 3 | Labeling | Approved | August 14, 1996 | — |
| Supplement | 2 | Labeling | Approved | July 10, 1991 | — |
| Supplement | 1 | Labeling | Approved | June 5, 1990 | — |
| Original application | 1 | Approved | March 19, 1984 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260112). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Apply to the affected area as a thin film from two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.
Description
openFDA Drug LabelingDESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Triamcinolone acetonide is chemically pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-(11β, 16α)- with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50. Its structural formula is: Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.025% contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.1% contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.5% contains 5 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. TA structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS )
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Triderm (Triamcinolone Acetonide Cream USP), 0.025% is supplied in: 15 grams tube NDC 0316-0165-15 85.2 grams tube NDC 0316-0165-85 454 grams jar NDC 0316-0165-16 Triderm (Triamcinolone Acetonide Cream USP), 0.1% is supplied in: 28.4 grams tube NDC 0316-0170-01 85.2 grams tube NDC 0316-0170-03 Triderm (Triamcinolone Acetonide Cream USP), 0.5% is supplied in: 15 grams tube NDC 0316-0175-15 454 grams jar NDC 0316-0175-16
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0316-0165-15 | 0316-0165 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0165-15) / 15 g in 1 TUBE | March 25, 2015 |
| 0316-0165-16 | 0316-0165 | Crown Laboratories | 1 JAR in 1 CARTON (0316-0165-16) / 454 g in 1 JAR | March 25, 2015 |
| 0316-0165-85 | 0316-0165 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0165-85) / 85.2 g in 1 TUBE | March 25, 2015 |
| 0316-0170-01 | 0316-0170 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0170-01) / 28.4 g in 1 TUBE | March 19, 1984 |
| 0316-0170-02 | 0316-0170 | Crown Laboratories | 3 g in 1 POUCH (0316-0170-02) | November 20, 2007 |
| 0316-0170-03 | 0316-0170 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0170-03) / 85.2 g in 1 TUBE | March 19, 1984 |
| 0316-0175-15 | 0316-0175 | Crown Laboratories | 1 TUBE in 1 CARTON (0316-0175-15) / 15 g in 1 TUBE | March 25, 2015 |
| 0316-0175-16 | 0316-0175 | Crown Laboratories | 1 JAR in 1 CARTON (0316-0175-16) / 454 g in 1 JAR | September 1, 2017 |
| 0316-0165 | 0316-0165 | Crown Laboratories | — | March 19, 1984 |
| 0316-0170 | 0316-0170 | Crown Laboratories | — | March 19, 1984 |
| 0316-0175 | 0316-0175 | Crown Laboratories | — | March 19, 1984 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.